BioVie Announces Phase 2 Trial Assessing NE3107’s Pro-motoric Activity In Parkinson’s Disease Is Fully Enrolled
BioVie Inc., (NASDAQ:BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and